Movano Inc. (NASDAQ:MOVE – Get Free Report) CTO Michael Aaron Leabman sold 3,293 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $7.34, for a total transaction of $24,170.62. Following the sale, the chief technology officer owned 39,313 shares of the company’s stock, valued at $288,557.42. This trade represents a 7.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Michael Aaron Leabman also recently made the following trade(s):
- On Friday, January 9th, Michael Aaron Leabman sold 783 shares of Movano stock. The stock was sold at an average price of $7.27, for a total transaction of $5,692.41.
- On Thursday, January 8th, Michael Aaron Leabman sold 3,593 shares of Movano stock. The shares were sold at an average price of $7.26, for a total transaction of $26,085.18.
Movano Price Performance
Shares of NASDAQ:MOVE traded down $0.52 during midday trading on Monday, hitting $6.97. The company had a trading volume of 24,936 shares, compared to its average volume of 32,819. Movano Inc. has a 12-month low of $4.67 and a 12-month high of $58.76. The company has a fifty day moving average of $8.79 and a two-hundred day moving average of $7.57. The company has a market cap of $5.82 million, a price-to-earnings ratio of -0.64 and a beta of 0.79.
Analysts Set New Price Targets
A number of research firms have weighed in on MOVE. Weiss Ratings reiterated a “sell (e+)” rating on shares of Movano in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Movano to a “hold” rating in a research note on Saturday, December 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Movano has a consensus rating of “Sell”.
Check Out Our Latest Stock Report on Movano
Hedge Funds Weigh In On Movano
An institutional investor recently bought a new position in Movano stock. Citadel Advisors LLC purchased a new stake in Movano Inc. (NASDAQ:MOVE – Free Report) during the third quarter, according to its most recent filing with the SEC. The fund purchased 49,262 shares of the technology company’s stock, valued at approximately $28,000. Citadel Advisors LLC owned about 5.94% of Movano as of its most recent filing with the SEC. Institutional investors own 16.64% of the company’s stock.
Movano News Roundup
Here are the key news stories impacting Movano this week:
- Positive Sentiment: Short interest fell in December: as of Dec. 31 short interest dropped to 43,438 shares (‑29.1% vs Dec. 15). That represented roughly 5.8% of shares sold short and a days-to-cover of about 0.5, which reduces immediate squeeze risk and can be viewed as a short‑term positive for the stock.
- Neutral Sentiment: January short-interest report flagged a “significant increase” as of Jan. 12 but the published figures show 0 shares and an NaN change — an internal data/reporting inconsistency. Investors should treat this as unresolved data; a confirmed rise in short interest would be bearish, but the current entry looks like a reporting error and warrants watching for corrected filings.
- Negative Sentiment: Underlying fundamentals remain weak: most recent quarterly results showed a smaller-than-expected EPS loss but revenue was essentially negligible relative to estimates and the company reported extreme negative margins and return on equity. Those results underscore continued cash-burn and revenue execution risk for this very small‑cap company.
- Negative Sentiment: Low market cap and thin liquidity amplify moves: Movano’s market capitalization and average volume are small, so headline-driven flows (shorting, data corrections, or small trades) can produce outsized price swings. That structural risk likely contributes to the downward pressure today.
About Movano
Movano Health, Inc (NASDAQ: MOVE) is a health technology company focused on developing wearable devices for continuous biometric monitoring. The company’s core mission is to provide accessible, real-time health insights through noninvasive sensors, enabling individuals and care teams to track vital signs and physiological trends outside of traditional clinical settings.
Movano’s flagship product is a biometric monitoring ring designed to measure parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality.
Featured Stories
- Five stocks we like better than Movano
- A month before the crash
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Trump’s Hand-Written Letter Will Shock his Haters
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Movano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Movano and related companies with MarketBeat.com's FREE daily email newsletter.
